Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
about
Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic ReviewProgressive multiple sclerosisPrimary progressive multiple sclerosis: current therapeutic strategies and future perspectivesA new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis.Analysis of the psychometric properties of the Multiple Sclerosis Impact Scale-29 (MSIS-29) in relapsing-remitting multiple sclerosis using classical and modern test theory.Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results.Clinical trials in progressive multiple sclerosis: lessons learned and future perspectivesA Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.Therapeutic Advances and Future Prospects in Progressive Forms of Multiple SclerosisMultiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan.Disease-modifying treatments for progressive multiple sclerosis.Inflammation in neurodegenerative diseases--an update.Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis.Pharmacology: Cannabis in neurology--a potted review.Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.Cannabinoids: new promising agents in the treatment of neurological diseases.Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids.Outcome measurement in neurodegenerative disease: attributes, applications & interpretation.Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.Managing Disability in Progressive Multiple Sclerosis.Medical cannabis: Another piece in the mosaic of autoimmunity?Future placebo-controlled trials of disease modifying therapy in relapsing multiple sclerosis would be unethical: Commentary.Cannabinoid signaling in health and disease.Cannabis and Multiple Sclerosis-The Way Forward.Imaging outcome measures for progressive multiple sclerosis trialsModelling the natural history of primary progressive multiple sclerosis.Progressive MS trials: Lessons learned.Clinical outcome measures for progressive MS trials.How far away from having an effective treatment option for progressive multiple sclerosis are we?Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases.Therapeutic potential of medicinal marijuana: an educational primer for health care professionals.Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis
P2860
Q26782408-C4F7C7D0-C7BD-4D1C-9A4F-0C07B2541CD3Q26861772-10B7017F-3D0C-4B6B-8443-D95F93B27482Q29030703-3949A186-82E5-4DB4-8A14-FB7F985830A2Q30670447-3F4FCBC0-267F-4F0B-81F7-AD7924434F63Q33692762-82A16044-19F8-4B0D-A014-351096B946B5Q33768737-22F544A4-6638-46D3-A800-DE471CC33E99Q35182733-FA0BC916-E12B-4788-8BC7-EE0B6883EE36Q35865445-D0C48CC7-686E-49BC-AF31-3C8627127117Q36353053-034A682F-793D-4B81-94C9-1A3E818FE96AQ36484443-EB24A986-83E9-4250-B8C3-2FEFF964D39BQ38140702-77209C4A-4DC7-4366-880F-2CC29763FDC5Q38142030-107F4D86-A547-41DF-B152-B405B1F6D27AQ38170472-31B5681C-C560-4443-8E78-B7A7B3F3805FQ38196701-8342F2D0-6579-4B9E-AB7B-7127E56B4FF2Q38227110-72522298-C453-4F7A-ABFC-16FB40E34880Q38261541-217FED46-9815-46F5-A494-78CA068130DDQ38269376-2C0981C6-8ECE-46C4-8F9B-15708EC46779Q38299472-5097F51B-56FA-42B2-8F39-DCEA2E57E9CFQ38570993-0EF67170-08BD-41D2-BEBA-6C2A24BAEAD9Q38677868-CF6694C9-5635-4657-9895-A6515E7D7077Q38811069-8A38D70C-F485-4A58-BE6A-0E8D6554BBE7Q39012168-6B1CCACF-0732-4C09-A31C-9B7A14CF5988Q39151223-7543B56E-E53E-4952-B1C2-620FC33EFF7EQ39163671-20D95FFB-4231-43E1-B843-F0FA228E0E01Q41064815-D87BF2FD-18A6-42DF-BE83-99D5C9B4FD5EQ42660399-A57DA277-2E3E-464A-BBB8-8074002CDCC4Q43923618-43B482D7-CD46-4DF3-895E-CDAB61679ACCQ47892257-819B7275-B29F-4FD5-B75C-18B30CC742BBQ47892293-7C0445A0-9F45-4BB8-B14B-C33AD288D6B5Q48179465-F72659DC-2C62-438D-AFE1-25B076962FA5Q54958903-895063C5-19F8-4EDE-B0C9-B5E664B4637AQ55397242-D2B24BB4-84F5-4508-87A4-672070DBD6A4Q58775742-E86AEDAC-66AE-45AA-83BF-B2E9C9227187
P2860
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effect of dronabinol on progre ...... sed, placebo-controlled trial.
@en
Effect of dronabinol on progre ...... sed, placebo-controlled trial.
@nl
type
label
Effect of dronabinol on progre ...... sed, placebo-controlled trial.
@en
Effect of dronabinol on progre ...... sed, placebo-controlled trial.
@nl
prefLabel
Effect of dronabinol on progre ...... sed, placebo-controlled trial.
@en
Effect of dronabinol on progre ...... sed, placebo-controlled trial.
@nl
P2093
P2860
P921
P1433
P1476
Effect of dronabinol on progre ...... sed, placebo-controlled trial.
@en
P2093
Andrew Nunn
CUPID investigator group
David McManus
David Miller
David Wright
Jane Vickery
Jeremy Hobart
John Zajicek
Mayam Gomez Cano
Sharukh Mallik
P2860
P304
P356
10.1016/S1474-4422(13)70159-5
P577
2013-07-13T00:00:00Z
2013-09-01T00:00:00Z